On March 21, 2022, Ajay Madan, Ph.D., provided notice to the Chief Executive Officer of Crinetics Pharmaceuticals, Inc. (the Company) of his resignation as Chief Development Officer of the Company, to be effective April 1, 2022. In connection with Dr. Madan's resignation, it is expected that the Company will enter into a consulting agreement for a period of six months with Dr. Madan pursuant to which he will assist with the transition of his duties to others within the Company and to ensure the continuity of its programs while it searches for his replacement.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
49.5 USD | +3.28% | +3.68% | +38.88% |
May. 10 | Crinetics Pharmaceuticals Insider Sold Shares Worth $5,307,931, According to a Recent SEC Filing | MT |
May. 09 | Crinetics Pharmaceuticals Q1 Net Loss Widens | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.88% | 3.78B | |
+28.38% | 48.16B | |
-0.22% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.85% | 25.59B | |
-22.71% | 18.96B | |
+8.45% | 12.92B | |
+29.75% | 12.03B | |
-1.99% | 11.77B |
- Stock Market
- Equities
- CRNX Stock
- News Crinetics Pharmaceuticals, Inc.
- Crinetics Pharmaceuticals, Inc. Announces Resignation of Ajay Madan as Chief Development Officer, Effective April 1, 2022